R1 RCM Inc Overview
R1 RCM is the largest independent, end-to-end revenue cycle management ("RCM") provider serving U.S. healthcare providers, and since November 2024 it has been a private, sponsor-controlled platform executing an aggressive AI-first replatforming of its service model.
Company disclosure in the FY2023 Form 10-K put headcount at approximately 30,000 as of 31 December 2023, split roughly 11,800 full-time and 500 part-time in the United States and approximately 17,600 internationally. Third-party estimates diverge materially thereafter: Revelio Labs put global headcount at approximately 30,164 as of March 2026, down 1.8% year over year, with India at roughly 64.5% of the workforce, the United States at 29.6% and the Philippines at 4.2%. R1's own R37 microsite and a March 2026 company article reference "more than 34,000 RCM experts and global employees," and PitchBook lists 34,000. Indian entity filings (R1 RCM Global Private Limited) recorded 16,445 employees as of 31 May 2024; a June 2026 CSR release cited "over 17,000 employees across Delhi NCR, Hyderabad, Bangalore and Chennai." The 30,000 versus 34,000 gap likely reflects the inclusion or exclusion of contractors and recently acquired teams; the discrepancy is unresolved in public sources.
R1 is the scale incumbent in U.S. provider revenue cycle management and, since its 2024 leveraged take-private, the industry's most aggressive bet that the revenue cycle can be re-founded as a software platform rather than an offshore labour arbitrage. It serves over 3,700 hospitals, 93–95 of the top 100 U.S. health systems and more than 30,000 physicians, and touches over $1 trillion of net patient revenue. Its economic model is unusual: multi-year, risk-bearing operating partnerships in which R1 absorbs a customer's revenue cycle cost base and earns a negotiated cost-to-collect plus performance incentives, layered with higher-margin modular products sold into a vast installed base. The strategic wager under TowerBrook and CD&R is the Phare Operating System — an agentic AI platform launched in October 2025 — which is intended to break the historical linkage between revenue growth and headcount growth, and thereby re-rate a services multiple toward a software one.
What the company actually does
The revenue cycle is the sequence of administrative and financial processes that begins when a patient schedules or presents for care and ends when the provider has collected every dollar owed from payers and from the patient. It encompasses scheduling, pre-registration, insurance eligibility and benefits verification, prior authorisation, financial clearance and counselling, charge capture, clinical documentation improvement, medical coding, claim submission, denial management and appeals, underpayment recovery, patient billing and collections, cash posting, reconciliation and reporting.
R1 does not sell a single product into that process. It sells operational accountability for some or all of it. In its own words from the FY2023 Form 10-K, R1 describes itself as a leading provider of technology-driven solutions that transform the financial performance and patient experience for health systems, hospitals and physician groups, with scalable operating models that complement a healthcare organisation's existing infrastructure and drive sustainable improvements in net patient revenue and cash flow while reducing operating cost.
Independent characterisation. R1 is best understood as a hybrid of three businesses that most analysts persist in mis-classifying as one:
-
A risk-bearing business process outsourcer. Under the "operating partner" model, R1 hires the customer's revenue cycle staff, assumes the customer's third-party vendor contracts, and takes over the function. R1 books the gross cost of running that function as cost of services and books a negotiated fee as revenue. This inflates reported revenue and structurally depresses gross margin — R1's gross margin has run in a 17–22% band, which is not a software margin and was never meant to be. This is the dominant model: the FY2023 Form 10-K states that for FY2021, FY2022 and FY2023, substantially all net operating and incentive fees from end-to-end RCM services were generated under the operating partner model.
-
A contingency-fee revenue recovery business. Acquired principally through Cloudmed (2022) and Acclara (2024), this is the "modular" side: underpayment recovery, DRG validation, government reimbursement optimisation, clinical documentation integrity, and extended business office services. These are sold on contingency or transaction-volume fees, carry materially higher incremental margins, and are sold behind whatever RCM operation the customer already runs — including a competitor's.
-
An emerging enterprise software platform. Phare OS, launched October 2025 and materially expanded through 2026, is the attempt to convert the first two businesses into a licensable, agentic system of intelligence.
Revenue model and contract economics
R1 disaggregates revenue into three lines:
Net operating fees: gross base fees charged to end-to-end customers for operating their revenue cycle processes, less the corresponding costs of the customer's revenue cycle operations that R1 undertakes to pay under the RCM agreement (salaries and benefits of transitioned personnel, third-party vendor costs), less any shared cost savings. Recognised ratably as the performance obligation is satisfied; base fees are typically billed in advance of the quarter and paid monthly. Crucially, base fees lag cash collections, which is why customer cash-flow disruptions (the 2024 Ascension ransomware event being the canonical case) push R1 revenue into later periods rather than destroying it.
Incentive fees: performance-based fees tied to agreed improvements in customer financial or operating metrics, generally measured against a defined prior-period baseline. These are the most volatile line and the first to be impaired by outages, payer behaviour shifts, or customer instability.
Modular and other: fees from modular solutions, generally contingency-based where R1 is optimising revenue or reducing cost, and fixed-fee (correlated to a transaction volume metric) where R1 is supplying outsourced resources.
Contract duration. End-to-end agreements typically run seven to ten years, subject to termination rights. Modular agreements typically have initial terms of up to three years. Sales cycles run six to eighteen months (or longer) for operating partnerships and two to six months for modular.
Recurring revenue. In its January 2022 investor materials R1 characterised recurring revenue as greater than 90% of the total.
Value chain position, customers and end markets
| Metric | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Ascension-affiliated revenue as % of total net services revenue | 61 | 49 | 40 |
R1 sits between the provider and the payer, and increasingly attempts to sit inside the payer–provider interface. It is not a payer, not a clearinghouse in the classical Change Healthcare/Waystar sense, and not an EMR. It plugs into the provider's existing systems — the FY2023 Form 10-K states R1 has developed configurable interfaces and integrations with every major EMR, payer, clearinghouse and bank, and does not require changes to the customer's core patient care or financial systems.
Customer types: health systems and hospitals (acute), physician groups and specialty practices (ambulatory), and post-acute settings. End markets served are exclusively U.S. healthcare provider reimbursement across fee-for-service, patient self-pay, and value-based payment models.
Customer concentration. Hospital systems affiliated with Ascension have been R1's largest customer group in every year since formation. Net services revenue from Ascension-affiliated providers as a percentage of total:
The trend line is the single most important structural fact about R1's business over the last five years: the company has been systematically de-risking a customer concentration that was once existential. Post-FY2023 concentration is not publicly disclosed, but the Acclara/Providence transaction, the Sutter Health partnership and modular growth will have continued to dilute it.
Scale metrics (as last disclosed)
| Metric | Value | As of / source |
|---|---|---|
| Hospitals served | Over 3,700 | 31 Dec 2023, FY2023 Form 10-K |
| Top-100 U.S. health systems served | 93 (FY2023 10-K); 94 (March 2025, R37 launch); 95 (2026, R37 microsite and LeadIQ profile) | Various |
| Physicians served | Over 30,000 | 31 Dec 2023, FY2023 Form 10-K |
| Net patient revenue under coverage | More than $1 trillion | 31 Dec 2023, FY2023 Form 10-K |
| Patient encounters processed annually | Over 550 million | FY2023 Form 10-K |
| Annual payer transactions | Over 180 million | March 2025, R37 launch release |
| Proprietary payment algorithms / rules | Over 20,000 | FY2023 Form 10-K; reiterated 2025–26 |
| Annual workflow actions | 1.2 billion | March 2025, R37 launch release |
| Tasks automated annually | Over 200 million, equivalent to more than 5,000 FTEs of capacity | 31 Dec 2023, FY2023 Form 10-K |
| Prior authorisation orders processed annually | Approximately 39 million | January 2026, R1 Prior Authorization launch |
| Payer relationships | Over 95% of U.S. health insurance companies | FY2023 Form 10-K |
| Net patient revenue live on Phare OS | More than $76 billion | 18 June 2026, Phare Intelligence release |
Strategy
Stated strategy — the public-era formulation
In the FY2023 annual report letter, then-CEO Lee Rivas framed the strategy as leveraging best-in-class capabilities to deploy flexible models that meet customers where they are on their revenue cycle journey, with four 2024 focus areas: aligning go-to-market with customer needs; delivering results to customers; executing the technology roadmap to drive measurable results; and operational excellence to deliver improved financial performance.
Stated strategy — the private-era formulation
The language changed decisively after the take-private. The operative formulation is Joe Flanagan's, from 14 April 2026: R1 has fundamentally shifted healthcare revenue management to a technology-first model, and in 2026 is focused on scaling deployment of Phare OS across its customer base. The Phare launch release put it more starkly still: the launch builds on significant investments to transform healthcare revenue management from a labour-first to a technology-first paradigm.
Dr. Martin Seneviratne of R37 supplied the underlying economic argument in June 2026: the revenue cycle has been stuck in a reactive, transactional model for decades, with providers and payers locked in an expensive back-and-forth serving neither; Phare OS is intended to change the economics of that relationship by bringing hundreds of workflows and thousands of users onto one platform to move toward real-time adjudication — resolving claims as care happens rather than weeks later.
This is a genuinely different strategy from the one R1 pursued as a public company. The public-era strategy was: acquire capability, cross-sell it into a large installed base, and arbitrage labour cost offshore. The private-era strategy is: rebuild the delivery model as software, decouple revenue from headcount, and re-rate the asset.
Announced strategic initiatives, last 24 months
| Date | Initiative | Detail and intent |
|---|---|---|
| March 2025 | R37 AI lab with Palantir | Exclusive partnership embedding Palantir forward-deployed engineers in R1 operations. Target: comprehensive automation of coding, billing and denials management. Explicit framing of the market opportunity: administrative costs account for more than 40% of U.S. hospital expenses with over $160 billion spent annually on RCM |
| Mid-2025 | Khosla Ventures investment | Capital and AI expertise directed at R37. R1 characterised it as validation and catalyst for the strategy to lead the next phase of AI-driven innovation in the RCM ecosystem |
| June 2025 | Finance and corporate development team rebuild | Ricaurte to CFO, Bise to EVP Corporate Development and Strategy — signalling an active M&A programme |
| June 2025 | Physician RCM leadership | Wojczynski appointed President of the physician business, reinforcing a segment that had lost Pediatrix |
| October 2025 | Phare Health acquisition | AI-native inpatient coding and pre-bill CDI; team folded into R37 |
| October 2025 | Sierra partnership | AI-powered conversational experiences |
| October 2025 | Phare OS launch and Singing River exclusive | Platform launch with a live reference customer |
| January 2026 | Phare Audit and R1 Prior Authorization launches | Two of the three highest-value pre-bill workflows productised |
| February 2026 | par8o divestiture | Portfolio focus; exit of a non-core 340B asset acquired via Cloudmed |
| April 2026 | Phare OS expansion: Denials Management, AR Recovery, R37 New York | Coupled with a "flexible customer engagement model" — commercially significant, implying licensing/outcome-based constructs alongside traditional BPO fees |
| June 2026 | Payer Atlas and Phare Intelligence | Foundational intelligence layer; explicit path to real-time adjudication |
| June 2026 | Indore, India expansion | Approximately 500 associates by end-2026; entry into Tier-2 labour markets while simultaneously claiming to reduce labour dependence — a tension worth watching |
| August 2026 | Humata Health acquisition agreement | Touchless prior authorisation; expected close end of Q3 2026 |
ESG and sustainability commitments
R1 published five annual ESG reports through the 2024 report (released 22 April 2025). The strategy is aligned to the UN Sustainable Development Goals, SASB and TCFD. As of 2026 the company's newsroom describes a sustainability strategy focused on reducing greenhouse gas emissions, expanding renewable energy use, improving resource efficiency and supporting healthier communities through measurable environmental action. See §20 for detail and for the significant gaps.
Medium-term financial targets
None are publicly disclosed. R1 withdrew guidance in November 2024 and, as a private company, publishes no financial targets. The last public long-term target was a long-term adjusted EBITDA margin of approximately 30%, stated in January 2022 investor materials. The only quantified forward commitment in the current public record is directional: Flanagan's statement that 2026 is focused on scaling Phare OS deployment across the customer base.
Products & Services
Engagement models (the commercial chassis)
| Offering | Description | Target customer | Pricing model | Status |
|---|---|---|---|---|
| Operating Partnership / End-to-End | R1 assumes full responsibility for all or selected revenue cycle phases, including personnel, technology and process workflow. R1's employees become the revenue cycle staff; third-party vendor contracts are controlled by R1 directly or assumed from the customer | Health systems, hospitals, large physician groups | Net operating fees (gross base fee less assumed customer revenue cycle costs less shared savings) plus incentive fees; 7–10 year terms | Core, active |
| Co-Managed | R1 supplements the customer's existing RCM staff and processes with infused management, subject matter specialists and proprietary technology. Majority of personnel and vendor contracts remain with the customer and those costs do not flow through R1's P&L | Systems wanting to retain employment of staff | Fee structure netted against retained customer costs | Active but immaterial — substantially all end-to-end fees FY2021–FY2023 came from the operating partner model |
| Modular Solutions | Discrete solutions purchasable individually or bundled, deployable behind an incumbent RCM operation | All provider types, including competitors' clients | Contingency-based for revenue/cost optimisation; fixed fee correlated to transaction volume for outsourced resources; initial terms up to three years | Fastest-growing |
The five modular solution families (as defined in the FY2023 Form 10-K)
| Family | What it contains | Target customer | Notes |
|---|---|---|---|
| Functional Partnership | Functional outsourcing of targeted revenue cycle areas | Organisations needing focused support in specific functions | Includes Extended Business Office (EBO) services |
| Revenue Recovery | Acceleration of payer and patient cash collections; aged, complex and clinically challenged claims; denials | Systems with A/R backlogs | Automation and AI applied to a historically labour-intensive back-end process |
| Revenue Optimization | Identification of missed or underreported revenue via comprehensive payment review | Systems losing 0.5–1.0% of NPR annually to underpayments (R1's own market framing) | Includes Underpayment Recovery — Best in KLAS 2026 |
| Clinical Integrity | Documentation and coding accuracy improvement to maximise earned revenue | Mid-cycle owners | Clinical and auditing experts; anchor for DRG Validation and Phare Audit |
| Regulatory Navigation | Compliance-first optimisation of government reimbursement accuracy, pharmacy savings, and programme compliance | Hospitals with significant Medicare/Medicaid and 340B exposure | Government Reimbursement Services — Best in KLAS 2024, 2025, 2026 |
The Phare Operating System — flagship platform (launched 22 October 2025)
| Module / capability | Launch | What it does | Disclosed performance |
|---|---|---|---|
| Phare Data Platform | Foundational (2025) | Unifies clinical and financial data across the revenue cycle into a single ontology usable by all agents and applications | — |
| Phare Access | 2,025 | Smart patient access hub; scheduling, coverage verification, financial clearance, authorisation lifecycle | Powers R1 Prior Authorization |
| Phare Claim | 2,025 | Autonomous coding | Autonomous coding accuracy reported as high as 97%, with early strength in emergency room and physician office visit service lines |
| Phare Flow | 2,025 | Agentic denials and appeals workflows; conversational AI for payer calls | At launch, fully automating over 20% of payer documentation requests by dollar volume; targeted agentic coverage on nearly 40% of denied dollars by end-2025; expectation to complete over 70% of payer calls using conversational AI |
| Phare Audit | 8 January 2026 | AI-native coding and clinical documentation integrity operating pre-bill, with evidence-based, fully auditable recommendations; extends R1's DRG Validation ("DRG-V") intelligence | Positioned as the most comprehensive AI-native mid-cycle solution combining an AI clinical engine with human experts |
| Payer Atlas | 18 June 2026 | Continuous payer policy monitoring and codification | Monitors over 30,000 ongoing policy changes and over 20,000 proprietary billing rules (R37 disclosure) |
| Phare Intelligence | 18 June 2026 | RCM-native foundational intelligence layer powering every application on the platform | Together with Payer Atlas and the Data Platform, forms the foundation for "real-time adjudication" |
| Denials Management | 14 April 2026 | Embedded agents across the denials and appeals workflow; evidence-backed appeal generation from medical records; automated payer follow-up | Appeal times cut by up to 50%; elimination of payer hold time |
| AR Recovery | 14 April 2026 | Agentic accounts receivable recovery | Sold with a flexible customer engagement model |
Phare OS is positioned by R1 as healthcare's first revenue operating system, unifying intelligence, continuous learning and connectivity across the entire revenue cycle in a single platform. It is built on an AI-first architecture that prioritises pre-bill workflows — authorisation, utilisation review, documentation and coding — with the explicit design goal of preventing downstream denials rather than appealing them. Its capabilities are being extended monthly.
Named point solutions and legacy platforms
| Product | Origin | Description | Status |
|---|---|---|---|
| R1 Prior Authorization | Launched 15 January 2026 on Phare Access | End-to-end authorisation lifecycle: determination, submission, completion. Human-in-the-loop with more than 1,600 dedicated authorisation experts | Active. 68% of orders cleared in one hour; ~97% in one day; auth-related denial rate under 1%; claimed total spend reduction of up to 50% versus traditional approaches, against an industry cost of $35–50 per authorisation |
| DRG Validation (DRG-V) | Organic / Cloudmed | Inpatient DRG accuracy validation | Active; the intelligence substrate for Phare Audit |
| Scheduling Optimization | 2,026 | Managed service converting stalled and incomplete orders into scheduled visits | Active |
| R1 Intelligent Automation | Organic | Library of automations combining robotic process automation, computer vision/OCR, natural language processing, expert rules/machine learning, workflow integration and analytics | Active; over 200 million tasks automated annually, unlocking more than 5,000 FTE-equivalents of capacity |
| R1 Embedded AI | Organic, expanded with Microsoft from 2023 | Machine learning, NLP and generative AI applied in-workflow | Active; dependent on third-party infrastructure including Microsoft Azure |
| VisitPay | Acquired May 2021 for $300m | Patient financial experience, billing transparency and payment plans; deployed at Memorial Sloan Kettering among others | Active |
| SCI Solutions patient access / scheduling | Acquired 2020 | Enterprise scheduling, self-service appointment management, out-of-pocket estimation, online pre-registration | Active, subsumed into Phare Access |
| Cloudmed revenue intelligence platform | Acquired June 2022 | Cloud-based platform analysing medical records, payment data and insurance models to identify additional recoverable revenue | Active; core of the modular franchise |
| Physician Advisory Services (PAS) portal | Legacy | Electronic submission, tracking, review and audit of patient cases referred to R1's physician reviewers, with an embedded analytics engine | Active |
| Contract modeling platform | Organic | Models each payer contract to calculate maximum allowed reimbursement per claim; monitors health plan compliance with contract terms | Active |
| Workflow / rules engine | Organic | Orchestrates claim handling across automated and human workflows; described as the revenue cycle's "central nervous system" | Active; 20,000+ algorithms |
| Reporting and analytics platform | Organic | Over 300 proprietary reports derived from financial, process and productivity data | Active |
| Chart manager | Organic | Medical record deficiency management and chart completion workflow | Active |
| Cash posting automation | Organic | End-to-end cash posting including bank deposit to remittance matching, posting initiation, balancing and financial reporting | Active |
| Quality assurance platform | Organic | Standardised audit workflow, statistical sampling, domain-specific audit templates, staff feedback | Active |
| Host billing and coding system | Organic | For hospital-based physicians: coding, insurance billing, A/R and denials management, patient statements, cash posting | Active |
| par8o | Acquired via Cloudmed 2022 | 340B referral capture with pharmacy integrations | Divested to NuvemRx, 2 February 2026 |
R37 — the innovation vehicle
R37 is not a product but the engineering organisation that produces them. Launched 14 March 2025 in exclusive partnership with Palantir Technologies, it embeds Palantir forward-deployed engineers alongside R1 product, engineering and operations personnel. Its remit: autonomous coding, denials and appeals automation, payer policy intelligence, and payer–provider interaction optimisation. It is co-led by Dr. Martin Seneviratne and Lee Kupferman as Co-CEOs, with Mark Sithi as SVP of product. R37 gained the Phare Health team on that acquisition's close and will gain the Humata Health engineering and clinical teams on that deal's close. It operates from an original site plus a New York City location opened 14 April 2026.
Financial Narrative
Scope note. The five fiscal years presented are FY2019 through FY2023 — the last five years for which R1 published audited financial statements. FY2021 and FY2022 figures reflect the restatement announced 13 November 2023 and are as compiled by S&P Global Market Intelligence from the company's filings. Where an originally reported press-release figure differs materially it is noted in commentary. FY2024 and later are addressed separately in §6.6.
Income statement
Margins
Revenue CAGR FY2019–FY2023: 17.4%.
Commentary. The revenue line tells a clean acquisition story: organic growth in the low-to-mid teens, punctuated by step changes when Cloudmed (June 2022) and Acclara (January 2024) landed. FY2020's 7.1% deceleration is the COVID volume shock — elective procedure suspension flowed directly into R1's fee base with a lag.
The margin story is more interesting and is the crux of the take-private thesis. GAAP-derived EBITDA margin expanded from 11.8% to 24.1% over five years while gross margin barely moved — from 16.7% to 21.5%. That gap is entirely explained by the mix shift into modular and by a depreciation and amortisation line that exploded from $55.7 million to $278.3 million, most of it purchase-price amortisation from Cloudmed. In other words, roughly half of the reported EBITDA expansion is an artefact of how acquisitions are accounted for, not operating leverage on the legacy business. The company's own adjusted EBITDA margin — 18.9% in FY2020 to 27.2% in FY2023, which management characterised as approximately 27% up from 23% — is the more honest read, and even that is heavily modular-mix-driven.
Net income is the weak point and always was. R1 earned $12.0 million of GAAP net income in FY2019 on $1.19 billion of revenue and $3.3 million in FY2023 on $2.25 billion. FY2020's $115.2 million was flattered by a $55.7 million gain on the EMS divestiture and a 1.1% effective tax rate. FY2022 was a $63.3 million loss, driven by $99.2 million of merger and integration charges, $83.0 million of other unusual items and a step-up in interest expense from $18.9 million to $64.0 million. FY2021's headline is grotesque at the per-share level — a $505.0 million loss to common on $87.3 million of net income — because the January 2021 preferred conversion drove a $592.3 million deemed dividend. This is a non-cash accounting consequence of the TCP-ASC recapitalisation, not an operating event, but it is the reason casual screens show R1 as deeply unprofitable in 2021.
Note the restatement effect: R1 originally reported FY2021 GAAP net income of $97.2 million in its February 2022 press release; the restated figure carried forward is $87.3 million. Similarly, originally reported FY2021 revenue was $1,474.6 million against $1,475 million as compiled. The revenue restatement was immaterial; the earnings restatement was not.
Interest expense is the story of the last three years. From $18.9 million in FY2021 to $126.9 million in FY2023 — a nearly sevenfold increase driven by Cloudmed-related debt and rising rates. Management guided FY2024 interest expense to $160–165 million before the LBO. Post-LBO the figure is far higher (see §6.6 and §21).
Balance sheet
Commentary. The balance sheet is a photograph of an acquisitive company. Total assets grew 5.3x while goodwill and intangibles grew 9.4x, and by FY2022 intangible assets represented 81% of total assets. Tangible book value has been negative in every year of the period and reached -$1.46 billion in FY2022. This is normal for a services roll-up and abnormal for a company with sub-1% net margins — it means the equity value rested entirely on the durability of contracted cash flows, which in turn rested on Ascension, Sutter, Providence and a few hundred modular accounts.
Accounts receivable is the item to watch. DSO went from 27.5 days in FY2019 to 69.5 days in FY2022 before recovering to 58.9 days in FY2023 — a doubling. Part is Cloudmed's contingency-fee model, which inherently collects more slowly. Part is not: FY2023 included a $34.6 million provision for credit losses (versus $11.8 million in FY2022 and $0.7 million in FY2021), driven by specific customers under financial stress, including an $11.6 million reserve taken in Q2 2023 against a physician customer and a modular customer that filed for bankruptcy in Q1 2024. Provider financial distress is a direct credit exposure for R1, not merely a demand headwind.
Cash flow
Commentary. Operating cash flow is violently volatile for a business with 90%+ recurring revenue, which is itself diagnostic. The FY2022 figure of negative $9.9 million is the outlier that should have drawn far more scrutiny than it did at the time: it was driven by a $141.8 million adverse swing in other net operating assets and a $75.9 million receivables build during Cloudmed integration. FY2023's recovery to $340.1 million is genuine but partly a reversal of that working capital drag.
Capital expenditure has run at roughly 4–5% of revenue, and management guided FY2024 to approximately 5%. Because R1 capitalises internally developed software, this line is the best available proxy for technology investment — see §13.
R1 has never paid a common dividend. Buybacks totalled $251.7 million across the five years, executed against a $500 million authorisation increased by the board in January 2022. The January 2021 preferred conversion also involved a one-time $105 million cash payment to TCP-ASC, funded from the balance sheet; this is an equity-holder distribution in substance, and it flows through financing activities rather than as a dividend.
Ratio analysis
FY2019 return on equity and return on assets are computed on ending balances (prior-year balance sheet not in scope); FY2020–FY2023 use two-point averages. ROIC uses EBIT taxed at an assumed 25% over the sum of total debt plus equity less cash. These are analyst-derived, not company-reported.
Commentary. Three things stand out.
Interest coverage deteriorated monotonically from 9.78x in FY2021 to 2.09x in FY2023 — before the LBO added roughly $2.6 billion of incremental debt. This is the single most important pre-transaction metric and it explains why the take-private capital structure has so little room for operational disappointment.
Asset turnover collapsed from 1.28x to 0.45x, entirely because of goodwill. Every dollar of revenue is now supported by more than twice the balance sheet it required in 2019.
ROIC never justified the acquisition spend. R1 deployed roughly $1.33 billion of cash and approximately $4.1 billion of stock on acquisitions across the period, and ROIC went from 10.3% in FY2019 to 4.6% in FY2023. Even granting that purchase amortisation depresses the numerator, the trend is clear: the roll-up bought scale and mix, not returns.
Reconciliation of GAAP to adjusted EBITDA
R1 defined adjusted EBITDA as GAAP net income before net interest income/expense, income tax provision/benefit, depreciation and amortisation, share-based compensation, CoyCo 2, L.P. share-based compensation, and certain other items including business acquisition costs, integration costs, technology transformation, strategic initiatives and the global business services centre expansion project in the Philippines. The gap between GAAP EBITDA and adjusted EBITDA — $70.8 million in FY2023 and $66.6 million in FY2022 — is therefore mostly stock compensation and serially recurring "one-time" acquisition and integration charges.
FY2024 — the incomplete final year
R1 never reported a full FY2024. What exists publicly:
Trailing-twelve-month figures to 30 September 2024 as compiled by S&P Global: revenue $2,464 million; operating income $203.0 million; EBITDA $518.4 million; net loss $61.2 million; operating cash flow $291.4 million; free cash flow $186.4 million; cash and equivalents $167.3 million; total debt $2,314 million; net debt $2,143 million; total assets $5,749 million; equity $2,811 million.
Original FY2024 guidance issued 27 February 2024 was revenue of $2,625–2,675 million, GAAP operating income of $105–135 million and adjusted EBITDA of $650–670 million. This was revised in May 2024 to revenue of $2,600–2,640 million and adjusted EBITDA of $625–650 million following the Change Healthcare outage and a modular customer bankruptcy. Guidance was withdrawn entirely with the Q3 2024 release on 5 November 2024 owing to the pending acquisition.
FY2024 full-year, FY2025 and FY2026 financial statements are not publicly disclosed. Third-party revenue estimates for the private period range from approximately $2.4 billion (RocketReach) to $5 billion (LeadIQ); none is sourced to the company and all should be disregarded.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Revenue
| Metric | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Net services revenue (total, reported) | 1,475 | 1,806 | 2,254 |
Net operating fees (derived from quarterly disclosures) | — | — | 1,447 |
Incentive fees (derived from quarterly disclosures) | — | — | 117 |
Modular and other (derived from quarterly disclosures) | — | — | 690 |
Segment Revenue (Quarterly)
| Metric | Q4 2021 | Q2 2022 | Q3 2022 | Q4 2022 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|
Net operating fees | 332.0 | 318.3 | 324.2 | 344.4 | 357.8 | 368.0 | 369.0 | 381.5 | 374.6 |
Incentive fees | 35.8 | 29.9 | 20.8 | 25.9 | 30.8 | 30.1 | 24.1 | 15.6 | 21.7 |
Modular and other | 31.1 | 43.7 | 151.0 | 162.5 | 172.1 | 174.7 | 182.0 | 206.8 | 231.6 |
Net services revenue | 398.9 | 391.9 | 496.0 | 532.8 | 560.7 | 572.8 | 575.1 | 603.9 | 627.9 |
Group Entities
| Entity | Role |
|---|---|
R1 RCM Inc. (Delaware) | Top-level operating parent post-2022 reorganisation; former SEC registrant (CIK 1910851) |
R1 RCM Holdco Inc. (Delaware) | Former R1 RCM Inc. / Accretive Health entity (CIK 1472595); issuer of record on current press releases |
Raven Acquisition Holdings, LLC / Raven Parent Holdings, Inc. / Raven TopCo, L.P. | Take-private acquisition vehicles (TowerBrook/CD&R) |
R1 RCM Global Private Limited (India, CIN U74900DL2009PTC187041) | Principal Indian delivery entity; incorporated 28 January 2009; registered New Delhi; reported revenue of approximately ₹19,000 million (₹1,900 crore) for the year ended 31 March 2025 per Tracxn |
R1 RCM India Private Limited (India, CIN U85100DL2007PTC159815) | Secondary Indian entity; incorporated 27 February 2007; small headcount |
Income Statement and Margin Analysis (%)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Net services revenue (USD Mn) | 1,186.0 | 1,270.0 | 1,475.0 | 1,806.0 | 2,254.0 |
Revenue growth (%) | 36.57 | 7.08 | 16.10 | 22.50 | 24.79 |
Cost of services (USD Mn) | 987.8 | 1,021.0 | 1,161.0 | 1,447.0 | 1,770.0 |
Gross profit (USD Mn) | 198.3 | 249.0 | 313.7 | 359.5 | 484.5 |
Selling, general and administrative (USD Mn) | 104.4 | 101.3 | 122.0 | 172.5 | 220.0 |
Total operating expenses ex cost of services (USD Mn) | 114.4 | 104.7 | 128.9 | 174.4 | 219.3 |
Operating income / EBIT (USD Mn) | 83.9 | 144.3 | 184.8 | 185.1 | 265.2 |
Depreciation and amortisation (USD Mn) | 55.7 | 68.7 | 77.5 | 172.0 | 278.3 |
EBITDA, GAAP-derived (USD Mn) | 139.6 | 213.0 | 262.3 | 357.1 | 543.5 |
Adjusted EBITDA, company-defined (USD Mn) | — | 240.0 | 343.6 | 423.7 | 614.3 |
Net interest expense (USD Mn) | 29.1 | 17.3 | 18.9 | 64.0 | 126.9 |
Merger, restructuring and integration charges (USD Mn) | 26.2 | 36.3 | 23.6 | 99.2 | 104.3 |
Gain on sale of business (USD Mn) | 0.0 | 55.7 | 0.0 | 0.0 | 0.0 |
Pre-tax income (USD Mn) | 9.8 | 116.5 | 117.3 | -66.8 | 21.0 |
Income tax expense / (benefit) (USD Mn) | -2.2 | 1.3 | 30.0 | -3.5 | 17.7 |
Net income / (loss) (USD Mn) | 12.0 | 115.2 | 87.3 | -63.3 | 3.3 |
Preferred dividends and other adjustments (USD Mn) | 20.7 | 68.7 | 592.3 | 0.0 | 0.0 |
Net income / (loss) to common (USD Mn) | -8.7 | 46.5 | -505.0 | -63.3 | 3.3 |
EPS basic (USD) | -0.08 | 0.40 | -1.90 | -0.18 | 0.01 |
EPS diluted (USD) | -0.08 | 0.32 | -1.90 | -0.18 | 0.01 |
Dividends per share (USD) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Weighted average shares basic (M) | 112.0 | 116.0 | 266.0 | 352.0 | 419.0 |
Weighted average shares diluted (M) | 112.0 | 175.0 | 266.0 | 352.0 | 454.0 |
Stock-based compensation (USD Mn) | 18.6 | 24.1 | 76.6 | 64.9 | 71.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Gross margin (%) | 16.72 | 19.60 | 21.27 | 19.90 | 21.49 |
Operating margin (%) | 7.07 | 11.36 | 12.53 | 10.25 | 11.76 |
EBITDA margin, GAAP-derived (%) | 11.77 | 16.77 | 17.79 | 19.77 | 24.11 |
Adjusted EBITDA margin (%) | — | 18.90 | 23.30 | 23.46 | 27.25 |
Net income margin (%) | 1.01 | 9.07 | 5.92 | -3.50 | 0.15 |
Balance Sheet and Per-Share Data
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Cash and cash equivalents (USD Mn) | 92.0 | 173.8 | 130.1 | 110.1 | 173.6 |
Accounts receivable, current (USD Mn) | 89.4 | 122.2 | 157.4 | 344.1 | 363.8 |
Total current assets (USD Mn) | 216.7 | 355.4 | 364.7 | 564.5 | 633.3 |
Property, plant and equipment, net (USD Mn) | 194.8 | 151.5 | 143.6 | 245.3 | 236.2 |
Goodwill (USD Mn) | 253.2 | 375.3 | 544.6 | 2,640.0 | 2,629.0 |
Other intangible assets (USD Mn) | 164.7 | 174.1 | 274.0 | 1,521.0 | 1,318.0 |
Goodwill and intangibles combined (USD Mn) | 417.9 | 549.4 | 818.6 | 4,161.0 | 3,947.0 |
Total assets (USD Mn) | 929.1 | 1,189.0 | 1,438.0 | 5,122.0 | 4,960.0 |
Accounts payable (USD Mn) | 20.2 | 18.2 | 17.7 | 33.4 | 22.7 |
Total current liabilities (USD Mn) | 232.5 | 206.3 | 253.0 | 349.7 | 346.2 |
Short-term debt and current portion of long-term debt (USD Mn) | 24.3 | 34.2 | 25.8 | 69.4 | 72.8 |
Long-term debt (USD Mn) | 337.7 | 519.7 | 754.9 | 1,733.0 | 1,571.0 |
Total debt including leases (USD Mn) | 457.5 | 637.1 | 847.6 | 1,914.0 | 1,740.0 |
Net debt (USD Mn) | 365.5 | 463.3 | 717.5 | 1,804.0 | 1,567.0 |
Total liabilities (USD Mn) | 681.9 | 849.6 | 1,101.0 | 2,419.0 | 2,209.0 |
Total shareholders' equity (USD Mn) | 247.2 | 339.4 | 336.7 | 2,703.0 | 2,751.0 |
Working capital (USD Mn) | -15.8 | 149.1 | 111.7 | 214.8 | 287.1 |
Book value per share (USD) | 0.16 | 0.73 | 1.21 | 6.49 | 6.55 |
Tangible book value (USD Mn) | -399.8 | -461.5 | -481.9 | -1,459.0 | -1,196.0 |
Cash Flow and Margin Analysis (%)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Operating cash flow (USD Mn) | 113.9 | 59.9 | 256.5 | -9.9 | 340.1 |
Capital expenditure (USD Mn) | -61.0 | -49.3 | -51.7 | -93.5 | -102.5 |
Free cash flow (USD Mn) | 52.9 | 10.6 | 204.8 | -103.4 | 237.6 |
Free cash flow margin (%) | 4.46 | 0.83 | 13.89 | -5.72 | 10.54 |
Cash used for acquisitions (USD Mn) | 0.0 | -194.1 | -286.4 | -847.7 | 0.0 |
Proceeds from divestitures (USD Mn) | 0.0 | 128.3 | 0.0 | 0.0 | 0.0 |
Investing cash flow (USD Mn) | -61.0 | -115.1 | -332.1 | -949.5 | -102.8 |
Long-term debt issued (USD Mn) | 381.8 | 240.6 | 818.6 | 1,067.0 | 30.0 |
Long-term debt repaid (USD Mn) | -409.0 | -43.4 | -598.9 | -55.5 | -183.9 |
Share repurchases (USD Mn) | -11.0 | -71.9 | -72.8 | -69.5 | -26.5 |
Dividends paid to common (USD Mn) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Financing cash flow (USD Mn) | -25.3 | 137.9 | 31.4 | 943.0 | -173.9 |
Cash interest paid (USD Mn) | 26.5 | 15.8 | 17.3 | 61.0 | 126.5 |
Cash income tax paid (USD Mn) | 3.8 | 3.8 | 5.0 | 8.6 | 34.0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Return on equity (%) | 4.86 | 39.28 | 25.83 | -4.17 | 0.12 |
Return on assets (%) | 1.29 | 10.88 | 6.65 | -1.93 | 0.07 |
Return on invested capital (%) | 10.27 | 13.48 | 13.15 | 3.08 | 4.61 |
Current ratio (x) | 0.93 | 1.72 | 1.44 | 1.61 | 1.83 |
Total debt / equity (x) | 1.85 | 1.88 | 2.52 | 0.71 | 0.63 |
Net debt / GAAP EBITDA (x) | 2.62 | 2.18 | 2.74 | 5.05 | 2.88 |
Net debt / adjusted EBITDA (x) | — | 1.93 | 2.09 | 4.26 | 2.55 |
Interest coverage, EBIT / interest expense (x) | 2.88 | 8.34 | 9.78 | 2.89 | 2.09 |
Asset turnover (x) | 1.28 | 1.20 | 1.12 | 0.55 | 0.45 |
Days sales outstanding (days) | 27.5 | 35.1 | 39.0 | 69.5 | 58.9 |
Days payable outstanding (days) | 7.5 | 6.5 | 5.6 | 8.4 | 4.7 |
Cash conversion cycle (days) | 20.0 | 28.6 | 33.4 | 61.1 | 54.2 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | 9M 2024 |
|---|---|---|---|---|
Revenue (USD Mn) | 603.9 | 627.9 | 656.8 | 1,888.6 |
Revenue growth year over year (%) | 10.7 | 12.0 | 14.7 | — |
Adjusted EBITDA (USD Mn) | 152.2 | 156.1 | 148.2 | 456.5 |
GAAP net income / (loss) (USD Mn) | -35.1 | — | -19.9 | — |
Revenue by Region
| Metric | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
Revenue from United States (USD Mn) | 1,475.0 | 1,806.0 | 2,254.0 |
Revenue from Americas ex-US (USD Mn) | 0.0 | 0.0 | 0.0 |
Revenue from EMEA (USD Mn) | 0.0 | 0.0 | 0.0 |
Revenue from APAC (USD Mn) | 0.0 | 0.0 | 0.0 |
United States as % of total revenue | 100.0 | 100.0 | 100.0 |
Operating Metrics (thousands)
| Metric | FY2023 |
|---|---|
Employees located in the United States, full-time (thousands) | 11.8 |
Employees located in the United States, part-time (thousands) | 0.5 |
Employees located internationally, full-time (thousands) | 17.6 |
International employees as % of total | 58.9 |
Share Price and Financial Ratios (x)
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 YTD |
|---|---|---|---|---|---|---|
Average share price (USD) | 10.94 | 14.23 | 23.77 | 20.66 | 14.52 | 10.77 |
Average EV / NTM EBITDA (x) | 16.1 | 15.4 | 22.1 | 17.3 | 12.6 | 9.4 |
Average year-over-year revenue growth (%) | 12.5 | 14.8 | 15.8 | 17.4 | 16.8 | 14.1 |
Average year-over-year EBITDA growth (%) | 57.0 | 37.7 | 22.2 | 24.7 | 20.2 | 17.6 |
Valuation Snapshot
| Metric | Value |
|---|---|
Final trade price, 18 November 2024 (USD) | 14.31 |
Merger consideration (USD per share) | 14.30 |
52-week high before delisting (USD) | 15.12 |
52-week low before delisting (USD) | 8.87 |
Twelve-month return to delisting (%) | 33.2 |
Shares outstanding at final filing (millions) | 422.4 |
Equity market capitalisation at final trade (USD Bn) | 6.04 |
Five-year share price return to Indian investors in local currency terms | 0.0% share price return, 24.4% dollar appreciation |
Enterprise value (USD Bn) | 8.9 |
EV / FY2023 revenue (x) | 3.95 |
EV / FY2023 adjusted EBITDA (x) | 14.49 |
EV / FY2024 guided adjusted EBITDA midpoint of 637.5 (x) | 13.96 |
Implied NTM EBITDA multiple of the New Mountain proposal at $13.75 (x) | 12.4 |
Implied NTM EBITDA multiple at $14.00 (x) | 12.6 |
Premium to unaffected close of 23 February 2024 (%) | 29 |
Premium to close of 31 July 2024 (%) | 11 |
Dividends & Capital Returns
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Share repurchases (USD Mn) | 11.0 | 71.9 | 72.8 | 69.5 | 26.5 |
Capital Instruments
| Instrument | Amount (USD Mn) | Tenor | Pricing | Notes |
|---|---|---|---|---|
Senior secured Term Loan B | 3,100 | 7 years | Talk of SOFR + 350–375bps, 0% floor, OID 99.5, with a 25bps step-down at 0.5x inside closing first-lien leverage; six months of 101 soft call protection. Yield to maturity at talk approximately 8.52–8.78% | Covenant-lite |
Delayed-draw term loan | 200 | Available 24 months | No ticking fee for first 60 days, 50% of margin days 61–90, 100% thereafter | — |
Senior secured notes | 1,300 | 7 years | Priced 24 October 2024; upsized from $1,000m on an order book reported at approximately four times oversubscribed | — |
Senior secured revolving credit facility | 687.5 | 5 years | Undrawn at close | — |
Total committed debt | 5287.5 | — | — | Of which approximately $4,400m funded |
Credit Ratings
| Agency | Rating | Date | Status |
|---|---|---|---|
S&P Global Ratings | 'B+' issuer credit rating assigned | 2022 | Subsequently placed on CreditWatch in connection with the take-private |
Analyst Conclusions
Management guidance
None. R1 withdrew financial guidance with its Q3 2024 release on 5 November 2024 and, as a private company, issues none. The only forward commitment on record is directional and product-focused: Flanagan's April 2026 statement that R1 has fundamentally shifted healthcare revenue management to a technology-first model and that 2026 is focused on scaling deployment of Phare OS across the customer base.
The last quantified guidance in the public record was the revised FY2024 range of revenue $2,600–2,640 million and adjusted EBITDA $625–650 million.
Consensus growth expectations
None exist. No sell-side analyst covers R1. Any growth estimate for FY2025 or FY2026 circulating in commercial databases is modelled, not sourced. The only observable proxies for direction are: nine-month 2024 revenue of $1,888.6 million (running at approximately 12.4% year-over-year growth despite two major outages); the Phare OS adoption metric of more than $76 billion of NPR live by June 2026; and continued acquisition activity.
Bull case
1. The platform metric is real and compounding. Phare OS went from zero to live across providers representing more than $76 billion of net patient revenue in eight months, with Providence — 51 hospitals across seven states — publicly committing and Singing River serving as a mid-market proof point. If R1's coverage is $1 trillion of NPR, $76 billion represents roughly 7.6% penetration of its own base in under a year. At that trajectory, and with each new module (Prior Authorization, Audit, Denials, AR Recovery, Payer Atlas, Phare Intelligence) increasing revenue per NPR dollar, the mix and margin transformation the sponsors underwrote is plausibly achievable inside the hold period. Critically, this is not a promise — it is a disclosed adoption metric.
2. The pre-bill thesis is economically correct and R1 is structurally best-placed to execute it. The industry spends more than $200 billion a year contesting claims of which fewer than 2.5% are ultimately denied. That is not a denials problem, it is a submission-quality problem. R1 is the only major participant that simultaneously holds the operating relationship (so it can change the workflow), the data (550 million encounters, 20,000 payment algorithms, 30,000+ tracked policy changes) and now the AI engineering capacity (R37 with Palantir, Phare Health, Humata). Epic sees one system; Optum sees the payer side; Waystar sees the transaction. R1 sees the operation. Autonomous coding accuracy already reported as high as 97% and prior authorisation clearance of 68% within one hour are the early evidence.
3. Penetration, not share, is the growth engine — and the denominator is enormous. Roughly 70% of hospitals still manage billing in-house. R1's FY2023 revenue was approximately 1.4% of its own estimate of U.S. RCM spend. Provider margins are compressed, denials are rising, coding and CDI talent is scarce, and prior-authorisation regulation is forcing infrastructure investment. Every one of those pressures argues for outsourcing to a vendor with automation at scale. R1 does not need to take share from Optum or Ensemble; it needs to convert insourced work, and the conditions for that conversion have never been better.
Bear case
1. The capital structure leaves no room for the transition to be slow. Funded debt of roughly $4.4 billion against a $625–650 million EBITDA base implies opening leverage near 7x. Interest coverage was already 2.09x in FY2023 on $126.9 million of interest expense; post-LBO interest is a multiple of that. R1 generated $237.6 million of free cash flow in its best year of the last five and negative $103.4 million in FY2022. A single Ascension-scale disruption, a single major contract loss, or two years of flat EBITDA converts a leveraged growth story into a restructuring conversation. The structure works only if the technology-first thesis delivers margin expansion on schedule — and technology transitions in healthcare rarely run on schedule.
- It is also a co-investor in the buyer, which cuts both ways: alignment, or a counterparty with unusual leverage in a renegotiation. Layered on top is a most-favoured-customer clause that structurally caps R1's pricing across its entire book. The single most important fact about R1's forward earnings is undisclosed.
3. R1 may be building a platform into a market that Epic is about to make a feature. On 18 August 2026, the same day R1 announced the Humata acquisition, Epic debuted instant prior authorization checks at four health systems. Epic sits inside the clinical record, is already paid for, and does not need to win a competitive procurement to deploy. Waystar, meanwhile, generates 42% adjusted EBITDA margins to R1's 27%, is growing 22% in Q1 2026, holds approximately 111% net revenue retention, and was rated first overall in Black Book's Q1 2026 agentic AI RCM benchmark. Conifer has Google Cloud; New Mountain has assembled Smarter Technologies from Access Healthcare, SmarterDx and Thoughtful.ai. R1's exclusive Palantir alliance is a genuine asset, but the strategic window in which "agentic RCM" is differentiated may be measured in quarters, and R1 is attempting to cross it carrying 7x leverage and 30,000 employees whose work the platform is designed to eliminate.
Catalysts and monitorables — next twelve months
| Monitorable | Why it matters | Expected timing |
|---|---|---|
| Ascension contract renewal or non-renewal | 40% of last-disclosed revenue; ten-year term implies a 2026 decision point | Overdue; any disclosure would be highly material |
| Humata Health closing | Completes the pre-bill stack; integration into Phare Intelligence and Payer Atlas | End of Q3 2026 |
| Phare OS NPR-live metric | The only quantitative adoption disclosure R1 provides; progression from $76bn is the single best proxy for the strategy working | Next disclosure likely at a product launch |
| Delaware Chancery ruling on the motion to dismiss | Determines whether the take-private fairness litigation proceeds to discovery against TowerBrook and Ascension | Argued 2 June 2026; ruling pending |
| Headcount trajectory | The technology-first thesis requires revenue to grow while headcount does not. Third-party data shows headcount down 1.8% year over year in 2026 while India expands into Indore — a mixed signal | Continuous |
| Best in KLAS 2027 | Independent, provider-sourced quality validation; a decline would signal service degradation during the platform transition | Early 2027 |
| Further tuck-in acquisitions | Two AI acquisitions in eleven months plus a dedicated corporate development EVP suggests a repeatable programme | Continuous |
| Credit market signals | Secondary trading levels on the 2031 term loan and notes are the only real-time market read on R1's performance available to outsiders | Continuous |
| Major new enterprise wins or losses | Becker's and trade press track outsourcing decisions; R1 won one of thirteen tracked 2025 decisions | Continuous |
| Any FY2025/FY2026 financial disclosure | Would likely come via a rating agency action, a refinancing, or an eventual IPO filing | Unpredictable |
| Exit signalling | TowerBrook entered in 2016 and CD&R in 2024; a 2027–2029 exit window is conventional. An S-1 would restore full disclosure | 2027+ |
Analyst verdict
R1 is the most interesting asset in healthcare revenue cycle management and one of the most precariously financed. The strategic logic of the private-era pivot is sound and, unusually for an AI narrative, partially evidenced: autonomous coding at 97% accuracy in defined service lines, prior authorisation clearing 68% of orders within an hour, denials appeals cut by up to half, and a platform live across more than $76 billion of net patient revenue eight months after launch. R1 holds the one asset neither Epic nor Optum nor Waystar can assemble — the operating relationship and the cross-system data that comes with it — and it has bought the engineering capacity to exploit it through an exclusive Palantir alliance and two well-targeted acquisitions.
Against this sits a balance sheet that permits no error. Roughly $4.4 billion of funded debt against a $625–650 million EBITDA base is approximately 7x, layered on a business whose interest coverage had already fallen to 2.09x pre-transaction, whose free cash flow was negative as recently as FY2022, and whose GAAP net income has never exceeded $115 million and was $3.3 million in its last audited year. R1 is asking a levered BPO to become a software company while continuing to employ 30,000 people doing work the software is designed to eliminate.
And the single most consequential fact is not disclosed. The Ascension master agreement, at 40% of last-reported revenue and carrying a most-favoured-customer clause that caps pricing across the entire book, ran a ten-year term from February 2016. There has been no renewal announcement. Until that is resolved, no responsible valuation of R1 is possible.
Verdict: a genuinely differentiated platform with a credible technology thesis, wrapped in a capital structure and a concentration profile that convert ordinary execution risk into existential risk. Watch the Phare NPR metric and watch Ascension. Everything else is commentary.
SOURCE NOTE
Primary sources: R1 RCM Inc. Form 10-K for FY2023 (filed 27 February 2024) and FY2022; Forms 10-Q for Q1–Q3 2024 and prior periods; Forms 8-K containing quarterly earnings releases FY2021–FY2024; DEF 14A filed 12 April 2024 and 4 April 2023; Schedule 13E-3 filed 3 September 2024 and its final amendment; the 2023 Annual Report to Shareholders; and R1 RCM Holdco Inc. press releases distributed via GlobeNewswire and published at r1rcm.com from November 2024 through 18 August 2026. Financial statement compilation for FY2019–FY2023 and the trailing period to 30 September 2024 draws on S&P Global Market Intelligence data as presented by StockAnalysis.com, cross-checked against company press releases. Transaction and financing detail from R1, TowerBrook, Kirkland & Ellis, RBC Capital Markets and PitchBook LCD. Litigation detail from Bernstein Litowitz Berger & Grossmann case materials, Bloomberg Law and Law360 reporting. Peer financials from Waystar Holding Corp. and TruBridge, Inc. public earnings releases for FY2025. Market sizing from The Business Research Company, Mordor Intelligence, MarketsandMarkets, Polaris Market Research, Fortune Business Insights, Coherent Market Insights and Precedence/Towards Healthcare, each cited inline given the irreconcilable spread between them.
Where analyst-derived calculations appear — ratios in §6.4, leverage estimates in §21.7, and the FY2023 revenue category split in §4.2 — they are explicitly labelled as such. Where sources conflict — headcount, headquarters location, FY2021 net income pre- and post-restatement, and market size — both figures and the nature of the discrepancy are stated.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Appointed | Prior roles and background |
|---|---|---|---|
Joseph (Joe) Flanagan | Chief Executive Officer; Board member | Reappointed CEO 19 November 2024 (previously CEO May 2016 – January 2023; COO from April 2013; board member since May 2016; Executive Advisor to the CEO January–June 2023) | SVP of Worldwide Operations and Supply Chain at Applied Materials; President of Nortel Business Services (Aug 2009 – Feb 2010) and SVP of Global Operations at Nortel Networks (2007–2009); various roles at General Electric 1993–2006. 20+ years of management experience; instrumental in creating the R1 Performance Stack |
John Sparby | President | Appointed President 1 January 2023; joined R1 January 2004 | Formerly EVP and Chief Solutions and Customer Officer; earlier led the East Region and the Ascension Michigan market. Prior to R1, led large-scale end-to-end revenue cycle reengineering projects, primarily for academic health systems, at Stockamp & Associates |
Chris Ricaurte | Chief Financial Officer (and formerly Chief Transformation Officer) | CFO from 11 June 2025; joined as Chief Transformation Officer February 2025 | Nearly three decades of financial and operational experience; R1 CFO 2013–2019; subsequently CFO and Chief Operating Officer of VillageMD and co-CEO of Parsley Health. As CTO was responsible for M&A, global operations and the physician/specialty care business line |
Dave Wojczynski | President, Physician Revenue Cycle Management | 18 June 2025 | Healthcare executive with experience across revenue cycle management, data analytics and technology-enabled services |
Andy Brailo | Chief Commercial Officer | 6 February 2026 | Background not detailed in the announcement reviewed |
Eric Tagliere | Chief Information Officer | 9 June 2026 | Appointed to drive technology strategy, innovation and execution during the labour-first to technology-first transition |
Steve Albert | Chief Strategy and Growth Officer (formerly EVP and Chief Product Officer) | Chief Product Officer as of 2024; strategy/growth title in use August 2026 | Co-presented R1's June 2024 "Technology Teach-In" investor session |
Dr. Martin Seneviratne | Co-Chief Executive Officer, R37 | 2025–26 | Physician-technologist leading the agentic AI programme |
Lee Kupferman | Co-Chief Executive Officer, R37 | 2025–26 | Presented on AI in CDI and coding at HFMA Annual Conference, June 2026 |
Dan Bise | EVP, Corporate Development and Strategy | 11 June 2025 | Track record in organic and inorganic expansion in high-growth industries |
Estelle Barnes | Leader, Enterprise Customer Engagement and Partnerships | 28 October 2025 | 30+ years in healthcare and healthcare RCM; formerly Chief Client Officer at Receivable Solutions, Inc., where client engagement strategies earned Best in KLAS recognition |
Natalie Klotsche | EVP, Client Strategy and Value | In role February 2026 | Public voice on KLAS recognition and customer value |
Mark Sithi | SVP, Product (R37) | 2025 | Leads R37 product management in partnership with Palantir |
Executive Leadership Team (Annual)
| Executive | Role in FY2023 | Salary (USD) | Bonus (USD) | Stock awards (USD) | Option awards (USD) | Other (USD) | Total (USD) |
|---|---|---|---|---|---|---|---|
Lee Rivas | Chief Executive Officer | 900,000 | 1,015,200 | 12,240,021 | 0 | 4,155 | 14,159,376 |
John Sparby | President | — | — | — | — | — | 3,340,000 |
Competitive Landscape
Key Competitors
| Competitor | Type | Scale and positioning |
|---|---|---|
Optum (UnitedHealth Group), incl. Change Healthcare | End-to-end, technology, payer-adjacent | The largest RCM company by revenue. Unmatched payer data access via UnitedHealth. Structural conflict: providers are increasingly uneasy handing revenue operations to a payer-owned entity — R1's single most exploitable competitive vulnerability in Optum's position |
Ensemble Health Partners | End-to-end | R1's closest true peer in the enterprise end-to-end segment; won Children's Minnesota (December 2025) and Benefis Health System (September 2025) |
Conifer Health Solutions | End-to-end, value-based care | Tenet Healthcare subsidiary, Frisco/Dallas, Texas. 600+ clients, over $32 billion of NPR, over 17 million unique patient encounters annually, approximately $1.3 billion of revenue as of 2026. Google Cloud AI partnership announced November 2025. In January 2026 Tenet regained full ownership after CommonSpirit Health exited with a reported $1.9 billion contract termination payment — a landmark demonstration of what health system exits from RCM joint ventures now cost |
Waystar Holding Corp. (Nasdaq: WAY) | Software / payments | The software-native benchmark. FY2025 revenue $1,099.3 million, up 17%; adjusted EBITDA $462.1 million at a 42% margin; GAAP net income $112.1 million. Acquired Iodine Software for $1.3 billion in July 2025. Rated #1 overall in Black Book's Q1 2026 agentic and generative AI RCM benchmark. Expanded Google Cloud partnership |
Savista | End-to-end and modular | Private; scale competitor in mid-market and enterprise |
CorroHealth | Mid-cycle and coding | Private; aggressive consolidator |
FinThrive | RCM software | Private; co-developed the RCM Technology Adoption Model with HFMA |
TruBridge (Nasdaq: TBRG) | RCM for rural and community hospitals | FY2025 revenue $346.8 million, up 1.4%; adjusted EBITDA $68.7 million at 19.8%; GAAP net income $4.4 million. Announced a strategic review in 2026 |
Access Healthcare / Smarter Technologies | Offshore operations plus AI | New Mountain Capital combined Access Healthcare, SmarterDx and Thoughtful.ai into Smarter Technologies in May 2025. Notable: New Mountain is R1's former largest-or-second-largest shareholder and its unsuccessful take-private bidder, now building a direct competitor |
AGS Health | Coding, RCM services, AI | Launched the AGS AI Platform in 2022 |
Huron Consulting Group | Consulting and RCM performance | Public; advisory-led model |
Omega Healthcare Management Services / GeBBS / Vee Healthtek / Infinx | Offshore RCM operations | Cost-structure competitors in the offshore delivery layer. Infinx acquired i3 Verticals' RCM business for $96 million in May 2025 |
Epic Systems | EMR-native | The most dangerous long-term threat. Epic accounts for the largest share of the U.S. RCM market by some measures because its integrated EHR/RCM stack makes outsourcing optional. Epic debuted instant prior authorization checks at four health systems on 18 August 2026 — the same day R1 announced Humata. That coincidence is not coincidental |
Oracle Health (Cerner) | EMR-native | Legacy source of R1's RevWorks channel; now a competitor |
Parallon (HCA), Revology, Med-Metrix, Guidehouse, Hartzler Healthcare, Coronis Health | Various | Second-tier and specialist competitors active in 2025–26 outsourcing decisions |
Peer Comparison FY2023
| Metric | R1 RCM | Waystar | TruBridge | Conifer |
|---|---|---|---|---|
Latest disclosed annual revenue (USD Mn) | 2,254 | 1,099 | 347 | 1,300 |
Fiscal year of that revenue | 2023 | 2025 | 2025 | 2026 |
Revenue growth in that year (%) | 24.79 | 17.00 | 1.40 | — |
Adjusted EBITDA (USD Mn) | 614 | 462 | 69 | — |
Adjusted EBITDA margin (%) | 27.25 | 42.00 | 19.80 | — |
GAAP net income (USD Mn) | 3.3 | 112.1 | 4.4 | — |
GAAP net margin (%) | 0.15 | 10.20 | 1.27 | — |
Capital expenditure as % of revenue (proxy for R&D intensity) | 4.55 | — | — | — |
Net leverage (x) | 2.55 | 3.00 | — | — |
Recent Developments
Covering approximately February 2025 through 23 August 2026. Sources are R1/GlobeNewswire releases, court reporting and trade press.
Not identified in the public record for this period: * any layoff announcement, any guidance revision (none is issued), any regulatory enforcement action against R1, any credit rating action publicly reported, any customer loss announcement, and any Ascension contract renewal announcement. The absence of the last is notable.



